Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.75 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.75 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.75 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | FAP | Q12884 | 1/20 | 0.50 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3841473 | 0.95 | DPP4 (0.73) | DPP4DPP8DPP7HDAC2KCNH2 | |
| SCHEMBL3840913 | 0.95 | DPP4 (0.73) | DPP4DPP8DPP7HDAC2KCNH2 | |
| SCHEMBL16500323 | 0.94 | DPP4 (0.75) | DPP4DPP8DPP7HDAC2KCNH2 | |
| SCHEMBL3842883 | 0.88 | DPP4 (0.88) | DPP4DPP8DPP7HDAC2KCNH2 | |
| SCHEMBL3841908 | 0.86 | DPP4 (1.00) | DPP4DPP8DPP7HDAC2KCNH2 | |
| SCHEMBL3846154 | 0.86 | DPP4 (0.67) | DPP4DPP8DPP7KCNH2FAP | |
| Hydrochloric Acid SCHEMBL2710293 | 0.85 | DPP4 (0.98) | DPP4DPP8DPP7HDAC2DPP9 | |
| SCHEMBL3844288 | 0.84 | DPP4 (0.70) | DPP4DPP8DPP7KCNH2FAP | |
| SCHEMBL3840953 | 0.82 | DPP4 (1.00) | DPP4DPP8DPP7KCNH2FAP | |
| SCHEMBL3840959 | 0.80 | DPP4 (0.68) | DPP4DPP8DPP7KCNH2FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2116541-B1 | Proline derivatives and their use as dipeptidyl peptidase IV inhibitors | PFIZER PROD INC (US) | 2015-02-25 | — | — | EP | claimed |
| EP-2116541-A1 | Proline derivatives and their use as dipeptidyl peptidase IV inhibitors | Pfizer Products Incorporated (US) | 2009-11-11 | — | — | EP | claimed |
| JP-4227660-B2 | — | — | 2009-02-18 | — | — | JP | claimed |
| US-7465732-B2 | (2S,4S)-4-(piperazin-1-yl)pyrrolidine-2-methanone derivatives | PFIZER INC (US) | 2008-12-16 | — | — | US | claimed |
| JP-2007537231-A | — | — | 2007-12-20 | — | — | JP | claimed |
| US-20070099897-A1 | Therapeutic compounds | PFIZER INC | 2007-05-03 | — | — | US | claimed |
| EP-1753748-A1 | PROLINE DERIVATIVES AND THEIR USE AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | Pfizer Products Inc. (US) | 2007-02-21 | — | — | EP | claimed |
| US-20060079498-A1 | Therapeutic compounds | PFIZER INC | 2006-04-13 | — | — | US | claimed |
| WO-2005116014-A1 | PROLINE DERIVATIVES AND THEIR USE AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | claimed |
| US-20050256310-A1 | Therapeutic compounds | PFIZER INC | 2005-11-17 | — | — | US | claimed |
| EP-2116541-B1 | Proline derivatives and their use as dipeptidyl peptidase IV inhibitors | PFIZER PROD INC (US) | 2015-02-25 | — | — | EP | disclosed |
| EP-2116541-A1 | Proline derivatives and their use as dipeptidyl peptidase IV inhibitors | Pfizer Products Incorporated (US) | 2009-11-11 | — | — | EP | disclosed |
| US-7465732-B2 | (2S,4S)-4-(piperazin-1-yl)pyrrolidine-2-methanone derivatives | PFIZER INC (US) | 2008-12-16 | — | — | US | disclosed |
| US-7291618-B2 | Therapeutic compounds | PFIZER INC (US) | 2007-11-06 | — | — | US | disclosed |
| US-20070099897-A1 | Therapeutic compounds | PFIZER INC | 2007-05-03 | — | — | US | disclosed |
| EP-1753748-A1 | PROLINE DERIVATIVES AND THEIR USE AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | Pfizer Products Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060079498-A1 | Therapeutic compounds | PFIZER INC | 2006-04-13 | — | — | US | disclosed |
| WO-2005116014-A1 | PROLINE DERIVATIVES AND THEIR USE AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050256310-A1 | Therapeutic compounds | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256310-A1 | Therapeutic compounds | REN, SLC5A1, SLC5A2 | DPP4 26/4885DPP8 413/4885DPP7 274/4885 |
| US-20070099897-A1 | Therapeutic compounds | SLC5A2, SLC5A1, REN | DPP4 31/4885DPP8 404/4885DPP7 114/4885 |
| US-20060079498-A1 | Therapeutic compounds | SLC5A2, SLC5A1, REN | DPP4 31/4885DPP8 404/4885DPP7 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.